Picture of Linical Co logo

2183 Linical Co Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Momentum

Relative Strength (%)
1m-23.64%
3m-33.21%
6m-49.91%
1yr-56.46%
Volume Change (%)
10d/3m+110.46%
Price vs... (%)
52w High-50.69%
50d MA-15.18%
200d MA-33.96%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)3.48%
Valuation (ttm)IndustryMarket
Price to Book Value1.24
Price to Tang. Book2.26
Price to Free Cashflow5.39
Price to Sales0.78
EV to EBITDA3.42

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital10.29%
Return on Equity9.18%
Operating Margin8.6%

Financial Summary

Year End 31st MarUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue¥m11,313.4710,935.2410,279.3111,555.0912,51711,90012,3006.55%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-32.98-9.89+8.99+27.71+8.33n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Linical Co EPS forecast chart

Profile Summary

Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Directors

Last Annual
March 31st, 2023
Last Interim
December 31st, 2023
Incorporated
June 7th, 2005
Public Since
October 27th, 2008
No. of Shareholders
3,767
No. of Employees
759
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
jp flag iconTokyo Stock Exchange
Shares in Issue
22,586,436

2183 Share Price Performance

Upcoming Events for 2183

Dividend For 2183.T - 15.0000 JPY

Full Year 2024 Linical Co Ltd Earnings Release

Similar to 2183

Picture of 3-D Matrix logo

3-D Matrix

jp flag iconTokyo Stock Exchange

Picture of AnGes logo

AnGes

jp flag iconTokyo Stock Exchange

Picture of BrightPath Biotherapeutics Co logo

BrightPath Biotherapeutics Co

jp flag iconTokyo Stock Exchange

Picture of Carna Biosciences logo

Carna Biosciences

jp flag iconTokyo Stock Exchange

Picture of Chiome Bioscience logo

Chiome Bioscience

jp flag iconTokyo Stock Exchange

FAQ